416 related articles for article (PubMed ID: 30579984)
1. Micro- and nanotechnology approaches to improve Parkinson's disease therapy.
Torres-Ortega PV; Saludas L; Hanafy AS; Garbayo E; Blanco-Prieto MJ
J Control Release; 2019 Feb; 295():201-213. PubMed ID: 30579984
[TBL] [Abstract][Full Text] [Related]
2. Advances in nanomedicine for the treatment of Alzheimer's and Parkinson's diseases.
Hernando S; Gartziandia O; Herran E; Pedraz JL; Igartua M; Hernandez RM
Nanomedicine (Lond); 2016 May; 11(10):1267-85. PubMed ID: 27077453
[TBL] [Abstract][Full Text] [Related]
3. A neoteric annotation on the advances in combination therapy for Parkinson's disease: nanocarrier-based combination approach and future anticipation. Part II: nanocarrier design and development in focus.
Unnithan D; Sartaj A; Iqubal MK; Ali J; Baboota S
Expert Opin Drug Deliv; 2024 Mar; 21(3):437-456. PubMed ID: 38507231
[TBL] [Abstract][Full Text] [Related]
4. Colchicine protects dopaminergic neurons in a rat model of Parkinson's disease.
Salama M; Ellaithy A; Helmy B; El-Gamal M; Tantawy D; Mohamed M; Sheashaa H; Sobh M; Arias-Carrión O
CNS Neurol Disord Drug Targets; 2012 Nov; 11(7):836-43. PubMed ID: 23198691
[TBL] [Abstract][Full Text] [Related]
5. Nanotechnology-mediated nose to brain drug delivery for Parkinson's disease: a mini review.
Kulkarni AD; Vanjari YH; Sancheti KH; Belgamwar VS; Surana SJ; Pardeshi CV
J Drug Target; 2015; 23(9):775-88. PubMed ID: 25758751
[TBL] [Abstract][Full Text] [Related]
6. Nanodelivery of therapeutic agents in Parkinson's disease.
Lafuente JV; Requejo C; Ugedo L
Prog Brain Res; 2019; 245():263-279. PubMed ID: 30961870
[TBL] [Abstract][Full Text] [Related]
7. Biomaterials in the treatment of Parkinson's disease.
Krishnan UM
Neurochem Int; 2021 May; 145():105003. PubMed ID: 33657427
[TBL] [Abstract][Full Text] [Related]
8. Drug development in Parkinson's disease: from emerging molecules to innovative drug delivery systems.
Garbayo E; Ansorena E; Blanco-Prieto MJ
Maturitas; 2013 Nov; 76(3):272-8. PubMed ID: 23827471
[TBL] [Abstract][Full Text] [Related]
9. Drug Delivery Systems for Imaging and Therapy of Parkinson's Disease.
Gunay MS; Ozer AY; Chalon S
Curr Neuropharmacol; 2016; 14(4):376-91. PubMed ID: 26714584
[TBL] [Abstract][Full Text] [Related]
10. Nanoparticle technology for treatment of Parkinson's disease: the role of surface phenomena in reaching the brain.
Leyva-Gómez G; Cortés H; Magaña JJ; Leyva-García N; Quintanar-Guerrero D; Florán B
Drug Discov Today; 2015 Jul; 20(7):824-37. PubMed ID: 25701281
[TBL] [Abstract][Full Text] [Related]
11. Nanotechnology-based Drug Delivery for Alzheimer's and Parkinson's Diseases.
Nguyen-Thi PT; Ho TT; Nguyen TT; Vo GV
Curr Drug Deliv; 2024; 21(7):917-931. PubMed ID: 37424345
[TBL] [Abstract][Full Text] [Related]
12. Brain aging and Parkinson's disease: New therapeutic approaches using drug delivery systems.
Rodríguez-Nogales C; Garbayo E; Carmona-Abellán MM; Luquin MR; Blanco-Prieto MJ
Maturitas; 2016 Feb; 84():25-31. PubMed ID: 26653838
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Parkinson's disease : what's on the horizon?
Wu SS; Frucht SJ
CNS Drugs; 2005; 19(9):723-43. PubMed ID: 16142989
[TBL] [Abstract][Full Text] [Related]
14. Novel therapeutic interventions for combating Parkinson's disease and prospects of Nose-to-Brain drug delivery.
Ahmad J; Haider N; Khan MA; Md S; Alhakamy NA; Ghoneim MM; Alshehri S; Sarim Imam S; Ahmad MZ; Mishra A
Biochem Pharmacol; 2022 Jan; 195():114849. PubMed ID: 34808125
[TBL] [Abstract][Full Text] [Related]
15. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ
Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
[TBL] [Abstract][Full Text] [Related]
16. Neurotrophic factors for the treatment of Parkinson's disease.
Sullivan AM; Toulouse A
Cytokine Growth Factor Rev; 2011 Jun; 22(3):157-65. PubMed ID: 21689963
[TBL] [Abstract][Full Text] [Related]
17. Role of Neurotrophic Factors in Parkinson's Disease.
Tome D; Fonseca CP; Campos FL; Baltazar G
Curr Pharm Des; 2017; 23(5):809-838. PubMed ID: 27928963
[TBL] [Abstract][Full Text] [Related]
18. Modulation of endoplasmic reticulum stress in Parkinson's disease.
Tsujii S; Ishisaka M; Hara H
Eur J Pharmacol; 2015 Oct; 765():154-6. PubMed ID: 26297973
[TBL] [Abstract][Full Text] [Related]
19. Novel Targets for Parkinson's Disease: Addressing Different Therapeutic Paradigms and Conundrums.
Rane P; Sarmah D; Bhute S; Kaur H; Goswami A; Kalia K; Borah A; Dave KR; Sharma N; Bhattacharya P
ACS Chem Neurosci; 2019 Jan; 10(1):44-57. PubMed ID: 29957921
[TBL] [Abstract][Full Text] [Related]
20. Targeted delivery of nano-therapeutics for major disorders of the central nervous system.
Gao H; Pang Z; Jiang X
Pharm Res; 2013 Oct; 30(10):2485-98. PubMed ID: 23797465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
